Sökning: onr:"swepub:oai:DiVA.org:uu-210761" >
Effect of Temozolom...
Effect of Temozolomide in Patients with Metastatic Bronchial Carcinoids
-
- Crona, Joakim (författare)
- Uppsala universitet,Experimentell kirurgi
-
- Fanola, Irina (författare)
- Uppsala universitet,Enheten för radiologi
-
- Lindholm, Daniel P. (författare)
- Uppsala universitet,Kardiologi
-
visa fler...
-
- Antonodimitrakis, Pantelis (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Öberg, Kjell (författare)
- Uppsala universitet,Onkologisk endokrinologi
-
- Eriksson, Barbro (författare)
- Uppsala universitet,Endokrin tumörbiologi
-
- Granberg, Dan (författare)
- Karolinska Institutet,Uppsala universitet,Onkologisk endokrinologi
-
visa färre...
-
(creator_code:org_t)
- 2013-08-31
- 2013
- Engelska.
-
Ingår i: Neuroendocrinology. - : S. Karger AG. - 0028-3835 .- 1423-0194. ; 98:2, s. 151-155
- Relaterad länk:
-
https://urn.kb.se/re...
-
visa fler...
-
https://doi.org/10.1...
-
http://kipublication...
-
visa färre...
Abstract
Ämnesord
Stäng
- Introduction: Metastatic bronchial carcinoids are rare neoplasms, where efforts of medical treatment so far have been disappointing. A previous study from our center indicated that temozolomide might be of value. Materials and Methods: All patients with progressive metastatic bronchial carcinoid treated with tennozolomide as monotherapy at our center between 2004 and 2010 (n = 31) were included in this retrospective study. 14 tumors were classified as typical and 15 as atypical carcinoids, whereas 2 tumors could not be classified. Temozolomide was given on 5 consecutive days every 4 weeks. Toxicity was evaluable in 28 of 31 patients, and 22 patients were evaluable by RECIST 1.1. Results: There were no complete responses. A partial response was seen in 3 patients (14%), stable disease in 11(52%) and progressive disease in 7 patients (33%). Median progression-free survival was 5.3 months and median overall survival was 23.2 months from the start of temozolomide. Toxcities grade 3-4 were noted in 4 patients, thrombocytopenia (n =3) and leukopenia (n = 1). Conclusion: Temozolomide as monotherapy shows activity in metastatic bronchial carcinoids. Regimens combining tennozolomide with other agents (e.g. capecitabine and/or bevacizumab, everolimus, radiolabeled somatostatin analogues) should be further studied in these patients. Copyright (C) 2013 S. Karger AG, Basel
Nyckelord
- Bronchial carcinoid
- Chemotherapy
- Metastatic disease
- Typical carcinoid
- Atypical carcinoid
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas